FOLH1 and prostate cancer: In addition, the harmonization method might be utilized to reduce inter-scanner variability in measurement of SPECT/CT-derived absorbed doses in a variety of “theranostics” situations such as Tc-99m MAA SPECT/CT in Y-90 microsphere therapy, I-131 SPECT/CT in thyroid cancer therapy, and Lu-177-PSMA in prostate cancer therapy [32–34].